Exact Mass: 500.1898
Exact Mass Matches: 500.1898
Found 500 metabolites which its exact mass value is equals to given mass value 500.1898
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Fluticasone propionate
Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone propionate binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IκB (inhibits NF-κB). Corticosteroids are the most effective anti-inflammatory therapy for allergic diseases. They are believed to inhibit T helper cell type 2 (TH2 T-cell) activation through increased immunoregulatory T cell (CD4+CD25+) suppression (PMID: 15316506). Fluticasone propionate is marketed under the brand name Flixotide and Flixonase by Allen & Hanburys, and Flovent and Flonase by GlaxoSmithKline. Fluticasone propionate is only found in individuals that have used or taken this drug. Hanburys and Flovent and Flonase by GlaxoSmithKline.; Fluticasone propionate is a potent glucocorticoid often prescribed as treatment for asthma and allergic rhinitis. It is marketed with the brand name Flixotide and Flixonase by Allen & Fluticasone is a potent glucocorticoid often prescribed as treatment for asthma and allergic rhinitis. D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D000893 - Anti-Inflammatory Agents D018926 - Anti-Allergic Agents D003879 - Dermatologic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Austin
Austin is a mycotoxin produced by the food storage mould (Aspergillus ustus). These are sesquiterpenes containing a lactone ring. Mycotoxin production by the food storage mould (Aspergillus ustus).
Artonol C
Artonol C is found in breadfruit. Artonol C is a constituent of the bark of Artocarpus communis (breadfruit) Constituent of the bark of Artocarpus communis (breadfruit). Artonol C is found in breadfruit and fruits.
S)-2-(5(((1,2-Dihydro-3-methyl-1-oxobenzo(F)quinazolin-9-YL)methyl)amino)1-oxo-2-isoindolinyl)glutaric acid
Baohuoside II
Galactoarabinan
L-Tyrosine, N-(2-(methoxycarbonyl)phenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-
Rolapitant
Ikarisoside A
Baohuoside II is a natural product found in Epimedium grandiflorum, Epimedium diphyllum, and other organisms with data available. IKarisoside A (Icarisoside-A) is a natural flavonol glycoside and has anti-inflammatory properties. IKarisoside A (Icarisoside-A) is a natural flavonol glycoside and has anti-inflammatory properties.
2-((Z)-hepta-5-en-1,3-diynyl)tetrahydrofuran-2-beta-D-glucopyranosyl(1->2)-beta-D-glucopyranoside|panaxfurayne B
Orbiculin D
A dihydroagarofuran sesquiterpenoid that consists of dihydro-beta-agarofuran substituted by acetoxy group at position 1 and furoyloxy groups at positions 6 and 9 (the 1beta,6alpha,9alpha stereoisomer). Isolated from Celastrus orbiculatus, it exhibits inhibition of both NF-kappaB activation and nitric oxide production.
(3S)-3,7-anhydro-6,7-dehydroericanone 4-beta-D-glucopyranoside
(1R,4S,5R,6R,7R,8R)-3-Oxo-8-<5-(5-acetoxytiglyloxy)-tiglyloxy>-guaia-10(14),11(13)-dien-6,12-olide|(1R,4S,5R,6R,7R,8R)-3-Oxo-8-[5-(5-acetoxytiglyloxy)-tiglyloxy]-guaia-10(14),11(13)-dien-6,12-olide
O-Rutinoside-3-(3-Hydroxypropyl)phthalide|Pedirutinoside
5-[(1E)-2-(4beta-D-glucopyranosyloxyphenyl)ethenyl]-4,7-dimethoxy-3-methyl-2H-1-benzopyran-2-one
Dodoviscin A
dodoviscin A is a natural product found in Dodonaea viscosa with data available.
cipatrijugin G|methyl rel-[(4R,4aS,6R,7aR,8S,11aS,12aR)-4-(furan-3-yl)dodecahydro-6-hydroxy-4a,7a,9,9-tetramethyl-13-methylidene-2,7,10-trioxo-4H-6,12a-methanopyrano[4,3-b][1]benzoxocin-8-yl]acetate
(1R,2S,4S,5S,6R,7R,9S,10S)-1,2,9,15-tetraacetoxy-4,6-dihydroxy-8-oxodihydro-beta-agarofuran
Dodovisone B
Fluticasone propionate
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D000893 - Anti-Inflammatory Agents D018926 - Anti-Allergic Agents D003879 - Dermatologic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Fluticasone
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents CONFIDENCE standard compound; INTERNAL_ID 2831 D000893 - Anti-Inflammatory Agents D018926 - Anti-Allergic Agents D003879 - Dermatologic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Cys Cys Ile Tyr
Cys Cys Leu Tyr
Cys Cys Tyr Ile
Cys Cys Tyr Leu
Cys Glu His Ile
Cys Glu His Leu
Cys Glu Ile His
Cys Glu Leu His
Cys Phe Met Thr
Cys Phe Thr Met
Cys His Glu Ile
Cys His Glu Leu
Cys His Ile Glu
Cys His Leu Glu
Cys His Asn Gln
Cys His Gln Asn
Cys Ile Cys Tyr
Cys Ile Glu His
Cys Ile His Glu
Cys Ile Tyr Cys
Cys Leu Cys Tyr
Cys Leu Glu His
Cys Leu His Glu
Cys Leu Tyr Cys
Cys Met Phe Thr
Cys Met Thr Phe
Cys Asn His Gln
Cys Asn Gln His
Cys Gln His Asn
Cys Gln Asn His
Cys Thr Phe Met
Cys Thr Met Phe
Cys Tyr Cys Ile
Cys Tyr Cys Leu
Cys Tyr Ile Cys
Cys Tyr Leu Cys
Asp Glu His Thr
Asp Glu Thr His
Asp Phe Gly Tyr
Asp Phe Tyr Gly
Asp Gly Phe Tyr
Asp Gly Tyr Phe
Asp His Glu Thr
Asp His Met Val
Asp His Thr Glu
Asp His Val Met
Asp Met His Val
Asp Met Val His
Asp Thr Glu His
Asp Thr His Glu
Asp Val His Met
Asp Val Met His
Asp Tyr Phe Gly
Asp Tyr Gly Phe
Glu Cys His Ile
Glu Cys His Leu
Glu Cys Ile His
Glu Cys Leu His
Glu Asp His Thr
Glu Asp Thr His
Glu Glu His Ser
Glu Glu Ser His
Glu His Cys Ile
Glu His Cys Leu
Glu His Asp Thr
Glu His Glu Ser
Glu His Ile Cys
Glu His Leu Cys
Glu His Ser Glu
Glu His Thr Asp
Glu Ile Cys His
Glu Ile His Cys
Glu Leu Cys His
Glu Leu His Cys
Glu Ser Glu His
Glu Ser His Glu
Glu Thr Asp His
Glu Thr His Asp
Phe Cys Met Thr
Phe Cys Thr Met
Phe Asp Gly Tyr
Phe Asp Tyr Gly
Phe Phe Gly Met
Phe Phe Met Gly
Phe Gly Asp Tyr
Phe Gly Phe Met
Phe Gly Met Phe
Phe Gly Tyr Asp
Phe Met Cys Thr
Phe Met Phe Gly
Phe Met Gly Phe
Phe Met Thr Cys
Phe Thr Cys Met
Phe Thr Met Cys
Phe Tyr Asp Gly
Phe Tyr Gly Asp
Gly Asp Phe Tyr
Gly Asp Tyr Phe
Gly Phe Asp Tyr
Gly Phe Phe Met
Gly Phe Met Phe
Gly Phe Tyr Asp
Gly Met Phe Phe
Gly Met Met Tyr
Gly Met Tyr Met
Gly Tyr Asp Phe
Gly Tyr Phe Asp
Gly Tyr Met Met
His Cys Glu Ile
His Cys Glu Leu
His Cys Ile Glu
His Cys Leu Glu
His Cys Asn Gln
His Cys Gln Asn
His Asp Glu Thr
His Asp Met Val
His Asp Thr Glu
His Asp Val Met
His Glu Cys Ile
His Glu Cys Leu
His Glu Asp Thr
His Glu Glu Ser
His Glu Ile Cys
His Glu Leu Cys
His Glu Ser Glu
His Glu Thr Asp
His Ile Cys Glu
His Ile Glu Cys
His Leu Cys Glu
His Leu Glu Cys
His Met Asp Val
His Met Val Asp
His Asn Cys Gln
His Asn Gln Cys
His Gln Cys Asn
His Gln Asn Cys
His Ser Glu Glu
His Thr Asp Glu
His Thr Glu Asp
His Val Asp Met
His Val Met Asp
Ile Cys Cys Tyr
Ile Cys Glu His
Ile Cys His Glu
Ile Cys Tyr Cys
Ile Glu Cys His
Ile Glu His Cys
Ile His Cys Glu
Ile His Glu Cys
Ile Tyr Cys Cys
Leu Cys Cys Tyr
Leu Cys Glu His
Leu Cys His Glu
Leu Cys Tyr Cys
Leu Glu Cys His
Leu Glu His Cys
Leu His Cys Glu
Leu His Glu Cys
Leu Tyr Cys Cys
Met Cys Phe Thr
Met Cys Thr Phe
Met Asp His Val
Met Asp Val His
Met Phe Cys Thr
Met Phe Phe Gly
Met Phe Gly Phe
Met Phe Thr Cys
Met Gly Phe Phe
Met Gly Met Tyr
Met Gly Tyr Met
Met His Asp Val
Met His Val Asp
Met Met Gly Tyr
Met Met Tyr Gly
Met Ser Thr Tyr
Met Ser Tyr Thr
Met Thr Cys Phe
Met Thr Phe Cys
Met Thr Ser Tyr
Met Thr Tyr Ser
Met Val Asp His
Met Val His Asp
Met Tyr Gly Met
Met Tyr Met Gly
Met Tyr Ser Thr
Met Tyr Thr Ser
Asn Cys His Gln
Asn Cys Gln His
Asn His Cys Gln
Asn His Gln Cys
Asn Gln Cys His
Asn Gln His Cys
Gln Cys His Asn
Gln Cys Asn His
Gln His Cys Asn
Gln His Asn Cys
Gln Asn Cys His
Gln Asn His Cys
Ser Glu Glu His
Ser Glu His Glu
Ser His Glu Glu
Ser Met Thr Tyr
Ser Met Tyr Thr
Ser Thr Met Tyr
Ser Thr Tyr Met
Ser Tyr Met Thr
Ser Tyr Thr Met
Thr Cys Phe Met
Thr Cys Met Phe
Thr Asp Glu His
Thr Asp His Glu
Thr Glu Asp His
Thr Glu His Asp
Thr Phe Cys Met
Thr Phe Met Cys
Thr His Asp Glu
Thr His Glu Asp
Thr Met Cys Phe
Thr Met Phe Cys
Thr Met Ser Tyr
Thr Met Tyr Ser
Thr Ser Met Tyr
Thr Ser Tyr Met
Thr Tyr Met Ser
Thr Tyr Ser Met
Val Asp His Met
Val Asp Met His
Val His Asp Met
Val His Met Asp
Val Met Asp His
Val Met His Asp
Tyr Cys Cys Ile
Tyr Cys Cys Leu
Tyr Cys Ile Cys
Tyr Cys Leu Cys
Tyr Asp Phe Gly
Tyr Asp Gly Phe
Tyr Phe Asp Gly
Tyr Phe Gly Asp
Tyr Gly Asp Phe
Tyr Gly Phe Asp
Tyr Gly Met Met
Tyr Ile Cys Cys
Tyr Leu Cys Cys
Tyr Met Gly Met
Tyr Met Met Gly
Tyr Met Ser Thr
Tyr Met Thr Ser
Tyr Ser Met Thr
Tyr Ser Thr Met
Tyr Thr Met Ser
Tyr Thr Ser Met
Flutide
rolapitant
A - Alimentary tract and metabolism > A04 - Antiemetics and antinauseants > A04A - Antiemetics and antinauseants D018377 - Neurotransmitter Agents > D064729 - Neurokinin-1 Receptor Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent Rolapitant (SCH619734) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant does not interact with CYP3A4. Rolapitant shows potent anti-emetic activity in a ferret emesis model[1][2].
1,4-PHENYLENEBIS[[4-(4-AMINOPHENOXY)PHENYL]METHANONE]
[4,5,8-triacetyloxy-6-(1-acetyloxy-4-methylpent-3-enyl)naphthalen-1-yl] acetate
1843U89;(2S)-2-(5-{[(3-Methyl-1-oxo-1,2-dihydrobenzo[f]quinazolin-9-yl)me thyl]amino}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)pentanedioic acid
S)-2-(5(((1,2-Dihydro-3-methyl-1-oxobenzo(F)quinazolin-9-YL)methyl)amino)1-oxo-2-isoindolinyl)glutaric acid
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2021 - Thymidylate Synthase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D000970 - Antineoplastic Agents
(1S,3S)-3-ethyl-3,5,10,12-tetrahydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-azaniumyl-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(2S)-3-hydroxy-2-[[1-[[(2R)-2-[(1R)-2-methoxy-2-oxo-1-phenylethyl]piperidine-1-carbonyl]oxymethyl]pyridin-1-ium-3-carbonyl]amino]propanoic acid
N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide
6,9-difluoro-11-hydroxy-17-(3-hydroxy-2-oxopropyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioic acid S-(fluoromethyl) ester
N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide
N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide
N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide
N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide
2-[(1S,3S,4aS,9aR)-6-(benzenesulfonamido)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide
N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide
N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide
N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide
1,2-diacetyl-3-[beta-D-glucosyl-(1->6)-beta-D-galactosyl]-sn-glycerol
9-(2-Carboxy-4-isothiocyanatophenyl)-3,6-bis(diethylamino)xanthylium
(2S,3S,4S,5R)-6-[7-carbamoyl-5-hydroxy-1-(4-phenylbutan-2-yl)indol-6-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
(2S,3S,4S,5R)-6-[7-carbamoyl-6-hydroxy-1-(4-phenylbutan-2-yl)indol-5-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
[2-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropyl] acetate
13-deoxycarminomycin(1+)
An anthracyline cation that is the conjugate acid of 13-deoxycarminomycin, obtained by protonation of the amino group. Major microspecies at pH 7.3
ELN-441958
ELN-441958 is a potent, neutral, competitive and selective bradykinin B1 receptor antagonist with a Ki of 0.26 nM against native human bradykinin B1 receptor. ELN-441958 has high oral bioavailability, and has low CNS exposure in the mouse[1].
(1s,2s,3r,7s,8s,9r,13s)-3,8-dimethyl-13-{[(2z)-2-methylbut-2-enoyl]oxy}-12-methylidene-4,11-dioxo-10-oxatricyclo[7.3.1.0³,⁷]tridec-5-en-2-yl (2z)-2-[(acetyloxy)methyl]but-2-enoate
3,9-dihydroxy-4,5,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl 2-methylbut-2-enoate
(12r)-3,10,17-trihydroxy-7,7,21,21-tetramethyl-12-(prop-1-en-2-yl)-8,20,26-trioxahexacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁶,²⁵.0¹⁹,²⁴]hexacosa-1(14),2,4(9),5,10,16,18,22,24-nonaen-15-one
2-(3,5-diformyl-2,4,6-trihydroxyphenyl)-5,7-dihydroxy-3-isopropyl-4-(2-methylpropyl)-3,4-dihydro-2h-1-benzopyran-6,8-dicarbaldehyde
12'-hydroxy-2,2,2',6',9',13'-hexamethyl-16'-methylidene-6,11',15'-trioxo-10',14'-dioxaspiro[pyran-3,5'-tetracyclo[7.6.1.0¹,¹².0²,⁷]hexadecan]-6'-en-8'-yl acetate
methyl (3r)-4-{6-[(2r,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]-1,5-dihydroxy-9,10-dioxoanthracen-2-yl}-3-hydroxy-3-methylbutanoate
methyl 2-[6-(furan-3-yl)-11-hydroxy-1,5,15,15-tetramethyl-8,14,17-trioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-9-en-16-yl]-2-hydroxyacetate
(8s,9r,10s)-3,9-dihydroxy-4,5,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl (2e)-2-methylbut-2-enoate
(6s)-2-[2-(4-hydroxyphenyl)ethyl]-6-[2-(4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)ethyl]-5,6-dihydropyran-4-one
(8r,10s)-10-{[(2r,3r,4r,5r,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-1,8,11-trihydroxy-8-methyl-9,10-dihydro-7h-tetracene-5,12-dione
27'-hydroxy-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',17',22'-trione
methyl (2e)-3-[(1s,2r,4s,7s,8s,11r,12s,16r,18r)-7-(furan-3-yl)-18-hydroxy-1,8,15,15-tetramethyl-5,17-dioxo-3,6,14-trioxapentacyclo[9.7.0.0²,⁴.0²,⁸.0¹²,¹⁶]octadecan-12-yl]prop-2-enoate
4,7-dimethoxy-3-methyl-5-[(1e)-2-(4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)ethenyl]chromen-2-one
(4r,7r,7ar)-3,7a-dibenzyl-4-hydroxy-4,7-diphenyl-6,7-dihydro-1-benzofuran-2,5-dione
(9r)-8-[2-(4-hydroxyphenyl)ethyl]-4-methoxy-9-[(4-methoxyphenyl)methyl]-9h-xanthene-2,3,6-triol
(12'z,18'z,20'z)-6'-hydroxy-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',17',22'-trione
(8r,9r,10r)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl but-2-enoate
5-[(2r,3s)-8-formyl-5,7-dihydroxy-3-isopropyl-6-(3-methylbutanoyl)-3,4-dihydro-2h-1-benzopyran-2-yl]-2,4,6-trihydroxybenzene-1,3-dicarbaldehyde
2-{3-[(2s)-2,3-dihydroxy-3-methylbutyl]-4-hydroxy-5-(3-methylbut-2-en-1-yl)phenyl}-5,7-dihydroxy-3,6-dimethoxychromen-4-one
11,12,16-trimethyl (1r,12r,13r,16r,23r)-12-hydroxy-6,8-dioxa-11,20-diazahexacyclo[14.6.1.0¹,¹³.0²,¹⁰.0⁵,⁹.0²⁰,²³]tricosa-2(10),3,5(9),17-tetraene-11,12,16-tricarboxylate
3,8-dimethyl-13-[(2-methylbut-2-enoyl)oxy]-12-methylidene-4,11-dioxo-10-oxatricyclo[7.3.1.0³,⁷]tridec-5-en-2-yl 2-[(acetyloxy)methyl]but-2-enoate
(1'r,2s,3'r,8'r,12'e,18'e,20'e,24's,25's,27'r)-27'-hydroxy-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',17',22'-trione
16,18-dimethyl 18-hydroxy-23-methoxy-11,13,20-trioxa-3,16-diazaoctacyclo[15.6.2.0¹,¹⁹.0²,⁶.0³,²¹.0⁶,¹⁷.0⁷,¹⁵.0¹⁰,¹⁴]pentacosa-7(15),8,10(14)-triene-16,18-dicarboxylate
(1'r,2s,3'r,8'r,12'z,18'e,20'z,24's,25's,27'r)-27'-hydroxy-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',17',22'-trione
12-(acetyloxy)-6-chloro-14,15-dihydroxy-2,11,15-trimethyl-7-methylidene-3-oxo-4,18-dioxatetracyclo[8.7.1.0¹,⁵.0¹¹,¹⁶]octadecan-17-yl acetate
(1'r,2r,3'r,8'r,13'r,18'e,20'z,24'r,25's)-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',18',20'-triene-11',12',17',22'-tetrone
methyl (2e)-3-[(1s,2r,4s,7s,8s,11r,12s,16r,18s)-7-(furan-3-yl)-18-hydroxy-1,8,15,15-tetramethyl-5,17-dioxo-3,6,14-trioxapentacyclo[9.7.0.0²,⁴.0²,⁸.0¹²,¹⁶]octadecan-12-yl]prop-2-enoate
[(2s,3s,4s,5r)-3,4,5-trihydroxy-6-[(2s)-3-(octanoyloxy)-2-(propanoyloxy)propoxy]oxan-2-yl]methanesulfonic acid
5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}chromen-4-one
methyl 3-[7-(furan-3-yl)-18-hydroxy-1,8,15,15-tetramethyl-5,17-dioxo-3,6,14-trioxapentacyclo[9.7.0.0²,⁴.0²,⁸.0¹²,¹⁶]octadecan-12-yl]prop-2-enoate
methyl 3-[11'-(furan-3-yl)-3'-hydroxy-2',3,3,6',10'-pentamethyl-4',13'-dioxo-12',15'-dioxaspiro[oxirane-2,5'-tetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan]-6'-yl]prop-2-enoate
12alpha-Hydroxyevodol
{"Ingredient_id": "HBIN000707","Ingredient_name": "12alpha-Hydroxyevodol","Alias": "12alpha-hydroxyevodol; 12\u03b1-hydroxyevodol","Ingredient_formula": "C26H28O10","Ingredient_Smile": "CC1(C2=C(C(=O)C3(C(C24COC(=O)CC4O1)CC(C5(C36C(O6)C(=O)OC5C7=COC=C7)C)O)C)O)C","Ingredient_weight": "500.5 g/mol","OB_score": "19.40751811","CAS_id": "NA","SymMap_id": "SMIT01183;SMIT15841","TCMID_id": "31192;10117","TCMSP_id": "MOL003976","TCM_ID_id": "19312","PubChem_id": "129317030","DrugBank_id": "NA"}
atalantin
{"Ingredient_id": "HBIN017265","Ingredient_name": "atalantin","Alias": "NA","Ingredient_formula": "C27H32O9","Ingredient_Smile": "CC1(C2C(=O)C(C3(C(C2(CO1)C=CC(=O)OC)CCC4(C35C(O5)C(=O)OC4C6=COC=C6)C)C)O)C","Ingredient_weight": "500.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1955","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101593045","DrugBank_id": "NA"}